Navigation Links
Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
Date:2/29/2008

d and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products and services; the successful development of diagnostic and therapeutic products applying Rosetta's technology, all of which are in early stages of development; Rosetta's ability to obtain regulatory clearances or approvals for products, as may be required under applicable laws; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; the ability to obtain coverage and payment from health plans and payers for diagnostic and therapeutic products applying Rosetta's technology and Rosetta's short operating history; as well as those risks more fully discussed under "Key Information - Risk Factors" in Rosetta's Annual Report on Form 20-F for the year ended December 31, 2006 on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of today and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

ROSETTA GENOMICS LTD. AND ITS SUBSIDIARY (A development stage company)

CONSOLIDATED STATEMENTS OF OPERATIONS

U.S. dollars in thousands (except share and per share data)

Year ended Three Months ended

December 31, December 31,

2007 2006
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Rosetta Genomics Establishes Medical Advisory Board
2. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
3. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
4. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
5. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
6. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
7. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
8. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
9. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
10. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
11. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... DUBLIN , Aug. 19, 2014 Research ... Oxide Fuel Cells (SOFCs) - Global Strategic Business Report" ... the worldwide markets for Solid Oxide Fuel Cells (SOFCs) in ... US, Canada , Europe ... Annual estimates and forecasts are provided for the period 2012 ...
(Date:8/19/2014)... , Aug. 19, 2014 ... the addition of the "Spectroscopy Equipment ... report to their offering. ... for Spectroscopy Equipment and Accessories in US$ ... Spectroscopy (UV-Vis spectrophotometers, Raman Spectrometers, NMR-EPR Spectrometers, ...
(Date:8/19/2014)... Aug. 19, 2014   Synthetic Biologics, Inc. ... novel anti-infective biologic and drug programs targeting specific ... today that its novel C. difficile ... th Interscience Conference on Antimicrobial Agents and ... D.C. Synthetic Biologics, Senior ...
(Date:8/18/2014)... 19, 2014 2014 Deep Research ... a professional and in-depth research report on the ... information, including its definition, classification, application, and ... This research covers the international market analysis, including ... analysis covering macroeconomic environment & economic situation analysis. ...
Breaking Biology Technology:Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4
... Cephalon, Inc. (Nasdaq:,CEPH) today announced that it ... a lawsuit in U.S. District Court in Delaware ... Laboratories,Inc., for infringement of U.S. Patent Nos. 6,200,604 ... Cephalon product FENTORA(R) (fentanyl buccal,tablet) [C-II]. The 6,200,604 ...
... iCAD, Inc. (Nasdaq:,ICAD), an industry-leading provider of Computer-Aided ... Executive Officer, and,Darlene Deptula-Hicks, Executive Vice President and ... corporate update at the Seventh Annual,Needham and Company ... 2008 at 2:00 p.m., (Eastern Daylight Time) at ...
... changes and further organizational ... consolidation ... Paul LaViolette to retire ... that President and Chief Executive,Officer Jim Tobin will be extending his tenure at the Company. The ...
Cached Biology Technology:Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals 2Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals 3iCAD to Present at Seventh Annual Needham and Company Biotechnology and Medical Technology Conference 2Boston Scientific Announces CEO Jim Tobin to Extend Tenure 2Boston Scientific Announces CEO Jim Tobin to Extend Tenure 3Boston Scientific Announces CEO Jim Tobin to Extend Tenure 4Boston Scientific Announces CEO Jim Tobin to Extend Tenure 5
(Date:8/20/2014)... who have suffered concussions ready to return to action? ... high school athletes who head back on the field ... regression in their abilities to simultaneously walk and do ... changes in their balance and/or altered walking speed, was ... 12 had returned to activity in less than a ...
(Date:8/20/2014)... spiciness that is irresistible to some, but intolerable to ... their findings to develop a new drug candidate for ... inflammation or other problems. They reported their progress on ... in ACS, Journal of Medicinal Chemistry . , ... had pegged a compound called capsaicin as the active ...
(Date:8/20/2014)... Your chairs, synthetic rugs and plastic bags could one ... waste rather than petroleum, scientists are now reporting. The ... help the world deal with its agricultural and plastic ... . , Athanassia Athanassiou, Ilker S. Bayer and colleagues ... plastic,s popularity is constantly growing. In 2012, its production ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... Center for Climate Change (BC3) has analysed the expected economic impact ... the Kyoto Protocol for the period 2008-2012 and for the phase ... come out on top in comparison to sectors such as industrial ... Spain have an impact on the economy, in other words, making ...
... (VBI) at Virginia Tech have constructed a mathematical and ... to simulate the cellular and molecular changes underlying chronic ... to explore different interactions of cells in the immune ... in the colon, and identify intervention points to perhaps ...
... HOUSTON -- A novel approach detects genetically abnormal cells in ... abnormalities found in tumor cells and increase in number with ... scientists at The University of Texas MD Anderson Cancer Center ... Lung cancer patients in the study also had many times ...
Cached Biology News:CO2 reduction policies in Spain strengthen the services sector 2Math model of colon inflammation singles out dangerous immune cells 2Math model of colon inflammation singles out dangerous immune cells 3UT MD Anderson study ties abnormal cells in blood to lung cancer 2UT MD Anderson study ties abnormal cells in blood to lung cancer 3
... offers single pass sequencing of plasmids ... fueled by our high performance sequencing ... Phred20 bases per day. The key ... sequencing customers are rapid turnaround, high ...
... Agencourt offers quick turnaround sequencing of ... copy and high copy plasmids. Agencourt's world-class, ... million Phred20 bases per day. The ... Sequencing service are 24 48 hour ...
Sequencing and primer design rolled into one. Just give us your clone and a reference sequence, and we'll do the rest. Single-strand or double-strand coverage. Guaranteed results....
Anti-Wnt-2 Polyclonal Antibody Description: 100 g purified goat polyclonal antibody. Reacts with human/mouse/rat. Tested in Western blot/IP/IHC. Research Focus: signal transduction Storage...
Biology Products: